Tags

Type your tag names separated by a space and hit enter

[K-ras mutation in pancreatic juice from patients with pancreatic carcinoma].
Zhonghua Nei Ke Za Zhi. 1999 Oct; 38(10):673-6.ZN

Abstract

OBJECTIVE

Pancreatic neoplasm, which is considered as one of the most malignant tumors in humans, is now increasing steadily in frequency. The 5-year-survival rate is less than 5%. In order to detect it in early stage, we tried to analyze K-ras mutation in pancreatic juice collected during ERCP after injection of secretin. Mutation of coden 12 in exon 1 of K-ras gene was reported as high as 90% in pancreatic cancer, but much less in benign pancreatic disease.

METHODS

47 patients at Peking Union Medical College Hospital between 1994 and 1998 were enrolled. Pancreatic juice collected during ERCP after injection of 100u secretin, was briefly centrifuged and the sediment was resuspended with PBS. Pancreatic juice supernatant and pancreatic cells were stored at -80 degrees C separately. DNA of the cells and supernatant of the juice were extracted. K-ras point mutation was investigated in the DNA of these supernatant and cells by means of two-stage polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP).

RESULTS

When the supernatant of the pancreatic juice was used, the PCR successful rate was 82%, K-ras mutation rate of the pancreatic carcinomas was 71% (15/21) compared with 0% (0/7) in benign pancreatic disease (3 chronic pancreatitis, 3 insulinoma and 1 pancreatic cyst). When the centrifuged pancreatic cells were used, the successful rate increased to 96%, sixty-five percent (11/17) of pancreatic carcinomas had K-ras mutation; mutation was also detected in 1/7 of the cases with benign pancreatic diseases (an insulinoma). In total, 78% (21/27) of the cases with pancreatic carcinomas has mutant alleles compared with 8% (1/13) of the benign pancreatic diseases (P < 0.001) when pancreatic juice was used to detect K-ras gene point mutation. In terms of the location of the pancreatic cancer, K-ras mutation rate was not statistically different between the head (80%) and the body + tail (75%). The mutation rate did not vary with the size of the tumor.

CONCLUSION

Detection of coden 12 of K-ras mutation in pancreatic juice can be used in differentiating pancreatic carcinomas from benign pancreatic diseases. It has high sensitivity and specificity.

Authors+Show Affiliations

Department of Gastroenterology, Peking Union Medical College Hospital, Beijing 100730.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

11798705

Citation

Gong, X, et al. "[K-ras Mutation in Pancreatic Juice From Patients With Pancreatic Carcinoma]." Zhonghua Nei Ke Za Zhi, vol. 38, no. 10, 1999, pp. 673-6.
Gong X, Chen Y, Chen Y, et al. [K-ras mutation in pancreatic juice from patients with pancreatic carcinoma]. Zhonghua Nei Ke Za Zhi. 1999;38(10):673-6.
Gong, X., Chen, Y., Chen, Y., & Lu, X. (1999). [K-ras mutation in pancreatic juice from patients with pancreatic carcinoma]. Zhonghua Nei Ke Za Zhi, 38(10), 673-6.
Gong X, et al. [K-ras Mutation in Pancreatic Juice From Patients With Pancreatic Carcinoma]. Zhonghua Nei Ke Za Zhi. 1999;38(10):673-6. PubMed PMID: 11798705.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [K-ras mutation in pancreatic juice from patients with pancreatic carcinoma]. AU - Gong,X, AU - Chen,Y, AU - Chen,Y, AU - Lu,X, PY - 2002/1/19/pubmed PY - 2004/10/8/medline PY - 2002/1/19/entrez SP - 673 EP - 6 JF - Zhonghua nei ke za zhi JO - Zhonghua Nei Ke Za Zhi VL - 38 IS - 10 N2 - OBJECTIVE: Pancreatic neoplasm, which is considered as one of the most malignant tumors in humans, is now increasing steadily in frequency. The 5-year-survival rate is less than 5%. In order to detect it in early stage, we tried to analyze K-ras mutation in pancreatic juice collected during ERCP after injection of secretin. Mutation of coden 12 in exon 1 of K-ras gene was reported as high as 90% in pancreatic cancer, but much less in benign pancreatic disease. METHODS: 47 patients at Peking Union Medical College Hospital between 1994 and 1998 were enrolled. Pancreatic juice collected during ERCP after injection of 100u secretin, was briefly centrifuged and the sediment was resuspended with PBS. Pancreatic juice supernatant and pancreatic cells were stored at -80 degrees C separately. DNA of the cells and supernatant of the juice were extracted. K-ras point mutation was investigated in the DNA of these supernatant and cells by means of two-stage polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP). RESULTS: When the supernatant of the pancreatic juice was used, the PCR successful rate was 82%, K-ras mutation rate of the pancreatic carcinomas was 71% (15/21) compared with 0% (0/7) in benign pancreatic disease (3 chronic pancreatitis, 3 insulinoma and 1 pancreatic cyst). When the centrifuged pancreatic cells were used, the successful rate increased to 96%, sixty-five percent (11/17) of pancreatic carcinomas had K-ras mutation; mutation was also detected in 1/7 of the cases with benign pancreatic diseases (an insulinoma). In total, 78% (21/27) of the cases with pancreatic carcinomas has mutant alleles compared with 8% (1/13) of the benign pancreatic diseases (P < 0.001) when pancreatic juice was used to detect K-ras gene point mutation. In terms of the location of the pancreatic cancer, K-ras mutation rate was not statistically different between the head (80%) and the body + tail (75%). The mutation rate did not vary with the size of the tumor. CONCLUSION: Detection of coden 12 of K-ras mutation in pancreatic juice can be used in differentiating pancreatic carcinomas from benign pancreatic diseases. It has high sensitivity and specificity. SN - 0578-1426 UR - https://www.unboundmedicine.com/medline/citation/11798705/[K_ras_mutation_in_pancreatic_juice_from_patients_with_pancreatic_carcinoma]_ L2 - https://medlineplus.gov/pancreaticcancer.html DB - PRIME DP - Unbound Medicine ER -